CBS News: Botox tested to help treat depression and social anxiety

While Botox is commonly used for cosmetic purposes, doctors say the reasoning behind the treatment for depression may not be what you expect.

“We don’t believe it has anything to do with looks,” says researcher Dr. Eric Finzi of Chevy Chase Cosmetic Center.

Rather, he says it’s because facial expressions are part of the circuit of the brain related to mood.

Science of Smiling in HuffPost Healthy Living

Dr. Eric Finzi and Dr. Norman Rosenthal’s research study findings featured in The Science of Smiling by Andrew Merle for Huffington Post Healthy Living

When we are happy, our natural response is to smile. But if you flip that around, does the reverse hold true? When we smile, is our natural response then to be happy?

Science says yes.

In fact, even faking or forcing a smile reduces stress and makes you happier….

…Another study looked at the effect of facial expression on depression. The experimenters, Eric Finzi (cosmetic dermatologist) and Norman Rosenthal (professor of psychiatry at Georgetown Medical School) worked with 74 subjects who all had major depression, and either gave them a Botox injection between the eyebrows that prevented frowning, or a placebo saline injection that did not affect the facial muscles.

The findings showed that, six weeks after the injection, 52 percent of the non-frowning Botox group showed a reduction in their depression, compared to only a 15 percent improvement rate for the placebo group. The results indicate that putting on a happy face actually makes you happier.

It seems that the simple act of a physical smile, authentic or not, tricks your brain into thinking you’re actually happy. Smiling also triggers us to think back to joyful memories, further improving mood.

In addition to lifting mood and reducing stress, other research has shown that people who smile are thought to be more friendly and likeable, and smiling actually makes those around you cheerier as well.

All of this shows that the old sayings actually deliver great advice — it’s time to turn that frown upside down, grin and bear it, and say cheese!

LINK to Article

Botox for Depression, Eric Finz, Faces of Emotion

 

For more insight in to the study findings READ Dr. Eric Finzi’s Book, Face of Emotion: How Botox Affects Our Mood and Relationships

 

Forbes Magazine “Botox Seems To Ease Depression”

Forbes.com’s Matthew Herper, a reporter on the Pharma and Healthcare beat, covered the recent annual meeting of the American Psychiatric Association in Toronto and wrote about the collective data findings on Botox to treat depression. Herper writes, “the analysis of the data published so far presented here at the American Psychiatric Association in Toronto seem to support the idea that Botox injections in the face can ease depressed mood.” Read more.

LISTEN LIVE WNPR Radio Today 12/11 at 1:00PM

Colin McEnroe ShowDr. Eric Finzi will be a guest on NPR Boston’s The Colin McEnroe Radio Show today at approximately 1:06PM EST talking about the Botox for Depression research study findings published in the Journal of Psychiatric Research (May 2014). The study “Treatment of Depression with onabotulinumtoxinA: A Randomized Double-Blind, Placebo Controlled Trial” found that 52% of subjects suffering from moderate to severe depression showed a relief from depression after injection of botulinum toxin to the glabellar area between the eyes, compared with only 15% of those who received the saline placebo. A second phase to this study is in the works.

This year marks commemorates the 25th anniversary of the first approved uses of BOTOX® and to honor its heritage as a medical advancement. You can listen to the program LIVE at http://wnpr.org/programs/colin-mcenroe-show and click on “stream us live” link.

The following information is published on Allergan, the makers of Botox’s  website:

While BOTOX® Cosmetic (onabotulinumtoxinA) has become a household name, BOTOX® was the first botulinum toxin type A treatment to be approved by the U.S. Food and Drug Administration as an orphan drug for two rare, eye muscle disorders.  This journey, which started in 1989, began with the approval of BOTOX® to treat strabismus (a misalignment of the eyes, commonly known as crossed eyes) and blepharospasm (uncontrolled blinking of the eyelid).  Strabismus affects nearly four in every 100 adults,1 and blepharospasm affects an estimated 20,000 to 50,000 people in the United States, with 2,000 new cases diagnosed annually.2 Since that time, BOTOX® therapeutic has been approved for other significant medical conditions including Cervical Dystonia, Severe Underarm Sweating when topical agents don’t work sufficiently, Upper Limb Spasticity, Chronic Migraine, Overactive Bladder when an anticholinergic doesn’t work or the side effects are intolerable, and urinary incontinence due to overactive bladder caused by a neurologic condition when an anticholinergic doesn’t work or the side effects are intolerable.

“BOTOX® is an innovative product whose potential to treat medical conditions across a variety of therapeutic categories continues to expand even today,” said David E.I. Pyott, Chairman of the Board and Chief Executive Officer, Allergan.  “The more we research the medical value of this treatment, the more we learn about this biologic and the areas of clinical unmet need where it may provide some benefit.  Since BOTOX® was first approved 25 years ago, the list of indications it treats has grown exponentially – not just in the United States, but globally.  Today, physicians in 88 countries treat 27 different conditions with BOTOX® and the possibilities continue to grow with Allergan’s research.”3

The video, which outlines the 25-year history of development for BOTOX® therapeutic, features first-hand accounts from patients who chronicle their journey from diagnosis to treatment, as well as physicians who share their personal experiences in advancing the development of this brand, showcasing its therapeutic roots.

For each person that views the video, Allergan will support four patient advocacy organizations that are partnering with the company to help raise awareness, educate and support people living with any of the medical conditions currently being treated with BOTOX®.  Support will be given to:

  • Benign Essential Blepharospasm Research Foundation (BEBRF)
  • Dystonia Medical Research Foundation (DMRF)
  • National Headache Foundation (NHF)
  • National Association for Continence (NAFC)

“The history of BOTOX® therapeutic is really a remarkable story of how a substance from nature has been successfully harnessed for medical benefit,” said Scott Whitcup, M.D., Allergan’s Executive Vice President, Research and Development and Chief Scientific Officer, “It’s also a human interest story that starts with the scientists and the physicians who observed the impact of BOTOX® in treating certain medical conditions, tracked that impact and did something about it.  Without this pioneering spirit, we would not have been able to pursue the clinical development and FDA approval of many of the therapeutic indications we now have for BOTOX®.”

To learn more about BOTOX® and to view the 25th anniversary video please visitwww.BOTOX.com.

About BOTOX®(onabotulinumtoxinA)BOTOX® is a prescription-only medical product that contains tiny amounts of a highly purified botulinum toxin protein refined from the bacterium, Clostridium botulinum.  When injected at doses approved by the U.S. Food and Drug Administration (FDA) into a specific muscle or gland, BOTOX® neurotoxin is expected to produce a safe, as well as effective result, usually lasting up to approximately three to ten months, depending on the approved indication and on the individual patient.

BOTOX®was first approved in 1989 by the U.S. Food and Drug Administration (FDA) for the treatment of two eye muscle disorders, making it the first botulinum toxin type A product to be approved in the world.  Since then, BOTOX®has been recognized by regulatory authorities as an effective treatment for 27 different indications in approximately 88 countries, benefiting patients worldwide.

Today, BOTOX®neurotoxin is approved to treat a total of eight medical conditions in the United States, including:

  • the treatment of overactive bladder symptoms such as a strong need to urinate with leaking or wetting accidents (urge urinary incontinence), a strong need to urinate right away (urgency), and urinating often (frequency) in adults 18 years and older when another type of medicine (anticholinergic) does not work well enough or cannot be taken;
  • the treatment of leakage of urine (incontinence) in adults 18 years and older with overactive bladder due to neurologic disease who still have leakage or cannot tolerate the side effects after trying an anticholinergic medication;
  • the prevention of headaches in adults with chronic migraine who have 15 or more days each month with headache lasting four or more hours each day in people 18 years or older;
  • the treatment of increased muscle stiffness in elbow, wrist, and finger muscles in people 18 years and older with upper limb spasticity;
  • the treatment of the abnormal head position and neck pain that happens with cervical dystonia (CD) in people 16 years and older;
  • the treatment of certain types of eye muscle problems (strabismus) in people 12 years and older;
  • the treatment of abnormal spasm of the eyelids (blepharospasm) in people 12 years and older; and
  • the treatment of symptoms of severe underarm sweating (severe primary axillary hyperhidrosis) when medicines used on the skin (topical) do not work well enough in people 18 years and older.

Dr. Finzi To Present Research at World Congress of Psychiatry Meeting Sept. 18 in Madrid

Botulinum Toxin (aka Botox) to Treat Depression? 

3 Independent Studies Prove It’s Worth A Shot

Leading Researchers Including Dr. Eric Finzi, Dr. Alex Wollmer,  Dr. Kruger Tillmann and Dr. Michelle Magid To Present Data from Clinical Studies at the XVI World Congress of Psychiatry Meeting, on September 18, 2014 in Madrid, Spain

The authors of three independent double-blind, randomized, placebo controlled clinical trials will present “Botulinum Toxin, An Emerging Therapeutic for Depression” and their respective research study findings to mental health professionals at the XVI World Congress of Psychiatry (WCP2014) meeting in Madrid, Spain, on September 18th from 12:45-13:30 in Room 11 at the Madrid Congress and Convention Center

The WCP2014, organized by the World Psychiatric Association will take place September 14-18 in Madrid, and will focus on access, quality and humane care. Over ten thousand psychiatrists from all over the world are expected to be in attendance.

According to the World Health Organization, over 350 million people of all ages suffer from depression globally. As of 2012 in the United States, an estimated 16 million adults aged 18 or older had at least one major depressive episode in the past year. Unfortunately, most people never seek treatment. Left undiagnosed and untreated, depression can worsen, cause untold suffering, and may even result in suicide.

Oral antidepressants are designed to boost mood and relieve depression. However, one third of patients do not respond to oral medications. In addition, for some sufferers, side effects such as fatigue, nausea, insomnia, sedation and lack of sexual drive may be poorly tolerated. By contrast, botulinum toxin has few side effects in the doses used to treat depression.

Botulinum toxin is FDA approved to treat a wide variety of health issues including urinary incontinence, migraine headaches, cerebral palsy, excessive sweating, and cervical dystonia, among others. 

Botox for Depression, Eric Finzi MD, PhDIn the largest study to date on the effect of botulinum toxin on depression, researchers Eric Finzi, MD, PhD, and Norman E. Rosenthal, MD, found that 52% of subjects suffering from moderate to severe depression showed relief from depression after injection of botulinum toxin to the glabellar area between the eyes, compared with only 15% of those who received the saline placebo. The study, “Treatment of depression with onabotulinumtoxinA: A randomized, double-blind, placebo controlled trial” was published in Journal of Psychiatric Research, Volume 52 (May 2014). These findings help to confirm a novel concept for mental health – using facial expressions to influence thoughts and feelings. 

Dr. Eric Finzi, a dermasurgeon and artist in the Washington, DC, metropolitan area, made global headlines in 2006 when his pilot study was the first to report the inhibition of facial frowning with Botox injection could help depressed patients. In The Face of Emotion, How Botox Affects Our Mood and Relationships, published by Palgrave Macmillan in 2013, Finzi explains his groundbreaking research and study findings in narrative form, weaving personal stories and rich historical accounts to showcase how his theory came to light. Finzi’s thinking, which dates back to Charles Darwin and William James’s facial feedback theory, marshals together evidence from psychology, neuroscience, art, evolutionary biology, family and patients, to show that facial expressions are a central driving force of our emotions, and that there is an unlikely ally available to tame them: Botox.

Finzi explains, “Botulinum toxin’s inhibition of frowning gives us a novel tool to influence mood. We believe that the brain monitors the state of contraction of facial muscles, and this feedback to the brain is powerful. We look forward to presenting the results from the three clinical trials to the world psychiatric community.”

NBC Washington Features Botox for Depression Research

Dr. Eric Finzi and Sarah Bergman, a Botox for depression study patient, were interviewed by WRC-TV news anchor Barbara Harrison on Tuesday, April 1, 2014 about the latest study findings published in the Journal of Psychiatric Research in May 2014.

Dr. Eric Finzi on NBC Washington, WRC-TV mid-day with Barbara Harrison